SCHEMBL16419554

SCHEMBL16419554

CCCC1CCN(C(=O)OC(C)(C)C)C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
ATM Q13315 2/20 0.41
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
ALDH1A1 P00352 2/20 0.39
KMT2A Q03164 1/20 0.39
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37
KDM1A O60341 1/20 0.37
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
HPGD P15428 1/20 0.36
TP53 P04637 1/20 0.36
GPR119 Q8TDV5 1/20 0.35
ELANE P08246 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL627075 0.90 PDE4A (0.39) PDE4APDE4BPDE4CPDE4DATM
SCHEMBL28101090 0.90 PDE4A (0.43) PDE4APDE4BPDE4CPDE4DATM
SCHEMBL3733255 0.89 PDE4A (0.42) PDE4APDE4BPDE4CPDE4DATM
SCHEMBL12341085 0.89 PDE4A (0.42) PDE4APDE4BPDE4CPDE4DATM
SCHEMBL13384176 0.87 PDE4A (0.42) PDE4APDE4BPDE4CPDE4DATM
SCHEMBL14932456 0.86 PDE4A (0.42) PDE4APDE4BPDE4CPDE4DDDB1
SCHEMBL27397832 0.84 STS (0.47) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL27397829 0.84 STS (0.47) PDE4APDE4BPDE4CPDE4DKDM4E
SCHEMBL15578408 0.84 DDB1 (0.41) PDE4APDE4BPDE4CPDE4DDDB1
SCHEMBL585837 0.83 PDE4A (0.37) PDE4APDE4BPDE4CPDE4DATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150031674-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2015-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031674-A1 SERINE/THREONINE KINASE INHIBITORS PAK1, AKT1, RB1 PDE4A 3021/4885PDE4B 2838/4885PDE4C 3150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.